Invention Grant
- Patent Title: Aflibercept ophthalmic pharmaceutical composition
-
Application No.: US16305987Application Date: 2017-10-13
-
Publication No.: US10646546B2Publication Date: 2020-05-12
- Inventor: Guang-Jin Im , Byung-Jhip Ha , Na-Won Park , Yong-Seop Park
- Applicant: SAM CHUN DANG PHARM. CO., LTD.
- Applicant Address: KR Hwasseong-si, Gyeonggi-do
- Assignee: SAM CHUN DANG PHARM. CO., LTD.
- Current Assignee: SAM CHUN DANG PHARM. CO., LTD.
- Current Assignee Address: KR Hwasseong-si, Gyeonggi-do
- Agency: Vorys, Sater, Seymour and Pease LLP
- Agent Mih Suhn Koh
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@2a29d59 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@7feefba0
- International Application: PCT/KR2017/011293 WO 20171013
- International Announcement: WO2018/199408 WO 20181101
- Main IPC: A61K38/17
- IPC: A61K38/17 ; A61K9/00 ; A61K47/12 ; A61K47/26

Abstract:
Provided is an ophthalmic pharmaceutical composition having a certain pH, comprising aflibercept as an active ingredient and an acetate salt buffering agent, wherein the composition is free of an ionic tonicity agent, remarkably reduces the formation of dimeric and multimeric impurities, and maintains the biological activity in a high level for a long time, under the accelerated and stress conditions as well as under the cold storage condition.
Public/Granted literature
- US20190160145A1 OPHTHALMIC PHARMACEUTICAL COMPOSITION Public/Granted day:2019-05-30
Information query
IPC分类: